Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > APP Announces Positive Results of Intra-Arterial ABI-007

June 4th, 2003

APP Announces Positive Results of Intra-Arterial ABI-007

Abstract:
At the American Society of Clinical Oncology annual meeting held in Chicago, Illinois, American Pharmaceutical Partners, Inc. said that investigators from the Insituto dei Tumori in Milan, Italy, reported on their experience in 108 patients receiving high dose ABI-007, a novel cremophor-free protein engineered nanoparticle paclitaxel, by the intra-arterial route.

Source:
APP

Bookmark:

Related News Press

Nanomedicine

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013